



About Revonto

> About Malignant Hyperthermia (MH)

> Why Revonto?

> Frequently Asked Questions

> Ordering Information

> Contact Us

After Hours/Emergency Order Information
 Call: (866) 916-0581
 Sales Inquiries Call: (877) 411-USWM (8796)

A Malignant Hyperthermia Crisis
 >>> Watch the video

Clinical Pharmacology

Indications and Usage

Dosage and Administration

Preparation

How Supplied

About Revonto

Revonto offers a significant advancement in patient pharmacotherapy with its improved ease of reconstitution. This feature allows operating room teams to be better equipped to manage an MH crisis. US WorldMeds has introduced **Revonto** at the same cost-savings as its original generic product.

The use of **Revonto** in the management of malignant hyperthermia crisis is not a substitute for previously known supportive measures. These measures must be individualized, but it will usually be necessary to discontinue the suspect triggering agents, attend to increased oxygen requirements, manage the metabolic acidosis, institute cooling when necessary, monitor urinary output, and monitor for electrolyte imbalance.

Please see [full prescribing information](#) for **Revonto**.

Reverse the Crisis with Revonto



Revonto puts time on your side. Revonto is ready to administer in 20 seconds or until the solution is clear.

US Worldmeds has partnered with the Nursing CE Portal to offer 2 **FREE** online courses



FOR NURSES		FOR PHARMACISTS & PHARMACY TECHS
Malignant Hyerthermia: Perioperative Crisis 1 Contact Hour		Malignant Hyerthermia: The Pharmacist's Perspective 1 Hour of CE, .1 CEU

For More information on Malignant Hyperthermia please visit [The Malignant Hyperthermia Association of the United States \(MHAUS\)](#).

Home / What is Malignant Hyperthermia (MH)? / About Revonto / Frequently Asked Questions / Ordering Information / Contact Us
 Full Prescribing Information / Clinical Pharmacology / Indications and Usage / Dosage and Administration / How Revonto is Supplied
 Privacy Policy / Terms of Use / US WorldMeds Home

Indication

Revonto is indicated, along with appropriate supportive measures, for the management of fulminant hypermetabolism of skeletal muscle characteristic of malignant hyperthermia crises in patients of all ages. It is also indicated preoperatively and sometimes postoperatively, to prevent or attenuate the development of clinical and laboratory signs of malignant hyperthermia in individuals judged to be malignant hyperthermia susceptible.

Important Safety Information

Despite initial satisfactory response to i.v. dantrolene there have been reports of fatality, which involve patients who could not be weaned from dantrolene after initial treatment. The administration of i.v. dantrolene is associated with loss of grip strength and weakness in the legs, as well as drowsiness and dizziness. There are rare reports of pulmonary edema developing during treatment, in which the diluent volume and mannitol needed to deliver the drug possibly contributed. There have been reports of thrombophlebitis following administration of intravenous dantrolene. Tissue necrosis secondary to extravasation has been reported. There have been rare reports of urticaria and erythema possibly associated with the administration of i.v. dantrolene. Injection site reactions (pain, erythema, swelling), commonly due to extravasation, have been reported. Symptoms which may occur in case of overdose include, but are not limited to, muscular weakness and alterations in the state of consciousness (e.g., lethargy, coma), vomiting, diarrhea, and crystalluria.

For additional information, see [full prescribing information](#) for **Revonto**.

Revonto is a registered trademark of US WorldMeds, LLC

© 2013 US WorldMeds, LLC